Health Care • Biotechnology: Laboratory Analytical Instruments
$174.87 ▼ -6.28
(-3.47%)
MKT CAP: $49.30B • VOL: 2.76M
52W L $108 52W H $183
A // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-10-31 | FY 2024
FILED 2024-10-31 | FY 2023
FILED 2023-10-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.95B | $6.51B | $6.83B |
| YoY Revenue Growth % | +6.7% | -4.7% | — |
| Gross Profit | $3.64B | $3.54B | — |
| Gross Margin % | 52.4% | 54.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.48B | $1.49B | $1.35B |
| Operating Margin % | 21.3% | 22.9% | 19.8% |
| Net Income (GAAP) | $1.30B | $1.29B | $1.24B |
| EBITDA (Normalized) | $1.80B | $1.79B | $1.60B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.56B | $1.75B | $1.77B |
| Capital Expenditures (CapEx) | $407.0M | $378.0M | $307.5M |
| Free Cash Flow (FCF) | $1.15B | $1.37B | $1.46B |
| FCF Margin % | 16.6% | 21.1% | 21.4% |
| Return on Invested Capital (ROIC %) | 15.0% | 16.3% | 6.3% |
| Cash & Short-Term Equivalents | $1.76B | $1.47B | — |
| Total Debt (Short + Long Term) | $2.66B | $2.65B | $6.57B |
| Total Stockholders' Equity | $6.91B | $6.03B | $13.48B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR A.